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Taxane-platin chemotherapy for non-
small cell lung cancer (NSCLC) is
beneficial, yet most tumors become drug
resistant. Dalvi et al. find upregulation of
JumonjiC demethylases in clinical NSCLC
samples and preclinical models of
resistance. Resistant cells and tumors
show hypersensitivity to JumonjiC
inhibitors, suggesting a therapeutic
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Although non-small cell lung cancer (NSCLC) pa-
tients benefit from standard taxane-platin chemo-
therapy, many relapse, developing drug resistance.
We established preclinical taxane-platin-chemore-
sistance models and identified a 35-gene resistance
signature, which was associated with poor recur-
rence-free survival in neoadjuvant-treated NSCLC
patients and included upregulation of the JumonjiC
lysine demethylaseKDM3B. In fact, multi-drug-resis-
tant cells progressively increased the expression of
many JumonjiC demethylases, had altered histone
methylation, and, importantly, showed hypersensi-
tivity to JumonjiC inhibitors in vitro and in vivo.
Increasing taxane-platin resistance in progressive
cell line series was accompanied by progressive
sensitization to JIB-04 and GSK-J4. These JumonjiC
inhibitors partly reversed deregulated transcriptional
programs, prevented the emergence of drug-tolerant
colonies from chemo-naive cells, and synergized
with standard chemotherapy in vitro and in vivo.
Our findings reveal JumonjiC inhibitors as promising
therapies for targeting taxane-platin-chemoresistant
NSCLCs.Ce
This is an open access article under the CC BY-NINTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in the
United States (American Cancer Society, 2015; Howlader et al.,
1975–2012). Non-small cell lung cancer (NSCLC) accounts for
85% of all lung cancer cases, more than 50% of which are
already at an advanced stage at the time of diagnosis. Plat-
inum-based doublet chemotherapy is the standard of care for
advanced NSCLCs and is given in combination with third-gener-
ation cytotoxic agents such as paclitaxel (Scagliotti et al., 2008;
Schiller et al., 2002). Early-stage patients also receive platin-tax-
ane chemotherapy to shrink tumors prior to resection (neoadju-
vant therapy). Cancer relapse after chemotherapy poses a major
obstacle for lung cancer cure, andmultiple studies have reported
recurrence/drug resistance in 70% of treated patients (Martin
et al., 2002; Massarelli et al., 2003; d’Amato et al., 2007). Thus,
despite current advances in targeted therapy for lung cancer,
there is a large unmet clinical need to identify effective therapies
for chemotherapy-resistant NSCLCs.
The most commonly implicated mechanism for acquisition of
resistance to taxanes involves increased expression of drug
efflux transporters such as MDR1, resulting in cross-resistance
to other chemotherapies (Gottesman et al., 2002). Clinical trials
using MDR inhibitors have been unsuccessful because of asso-
ciated toxicity to normal tissues or lack of response due to collat-
eral mechanisms of resistance (Bradshaw and Arceci, 1998;
Szakács et al., 2006). Epigenetic drivers of tumor drug tolerancell Reports 19, 1669–1684, May 23, 2017 ª 2017 The Authors. 1669
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have recently gained attention owing to their ability to dynami-
cally alter transcriptional programs. Cell subpopulations surviv-
ing epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor or BRAFV600E inhibitor overexpress the histone lysine
demethylase KDM5A (Sharma et al., 2010) or KDM5B (Roesch
et al., 2013), respectively, and KDM5 inhibitors have recently
shown therapeutic potential (Vinogradova et al., 2016). T cell
acute lymphoblastic leukemia cells persisting gamma-secretase
inhibitors showed increased expression of BRD4 and sensitivity
to the small-molecule inhibitor JQ1 (Knoechel et al., 2014). These
studies suggest a role of epigenetic drivers in the acquisition
of the drug-tolerant state. This state might not only provide a
transition phase for surviving drug stress but also lead the way
to establishing permanent resistance mechanisms.
To study the progression ofNSCLC resistance to standard tax-
ane-platin combination therapy, we developed isogenic resistant
cell line variants through long-term drug treatment using cycles
of drug on/drug off therapy to mimic clinical regimens. We then
used these models to search for clinically relevant targets
for drug-resistant lung cancers by integrating genome-wide
mRNA expression profiles of resistant cell line variants and the
corresponding xenografts and by evaluating the preclinical resis-
tance signature for its association with recurrence-free survival
outcome in neoadjuvant-chemotherapy-treated NSCLC pa-
tients. Intriguingly, our studies uncovered epigenetic alterations
in chemoresistant cells encompassing several members of the
JumonjiC (JmjC) histone demethylase family. We asked whether
these epigenetic mechanisms conferred a survival advantage
that could be exploited therapeutically to abrogate NSCLC cells
that develop resistance to taxane-platin chemotherapy.
RESULTS
Long-Term Paclitaxel-Carboplatin-Treated NSCLC Cell
Lines Develop Progressive Increases in
Chemoresistance
To establish in vitro models of lung cancer chemoresistance, we
treated NSCLC cell lines with paclitaxel-carboplatin standard
chemotherapy, which was given in the clinically relevant 2:3 w/w
ratio. Our ongoing tests of >100 NSCLC lines identified H1299
and H1355 among a group of NSCLC cell lines that had 100- to
500-fold lower half inhibitory concentration (IC50) values than the
most resistant NSCLC lines and were thus selected as ‘‘parental’’Figure 1. Long-Term-Treated NSCLC Cell Lines Develop Progressively
(A and C) Dose-response curves for NCI-H1299 (A) and NCI-H1355 (C) cells afte
parental cell line; T[n], resistant variant generated after ‘‘n’’ cycles of doublet chem
combination (see Experimental Procedures for dosing details). Each data point r
(B and D) IC50 plots for H1299 (B) and H1355 (D) resistant cell line variants. IC50 va
Data represent IC50 mean ± SD of four or more replicate assays. p values are fro
(E and G) Resistance was validated in liquid colony formation assays. Represen
indicate concentration of paclitaxel (in nM) in the 2:3 w/w doublet.
(F and H) Dose-response curves for H1299 (F) and H1355 (H) were generated by c
additional plates were treated with lower doses starting from 40 nM highest dos
(I and J) H1299 parental (I) and H1299 T18 (J) tumor-bearing mice were randomiz
3 weeks. Tumor volumes were measured after each treatment cycle (C1, C2, and
ANOVA followed by Sidak’s multiple comparison tests. H1299 parental xenograf
xenografts, two-way ANOVA: p value not significant (n.s.).
See Table S1 and related Figures S1–S3.cells to develop drug-resistant variants. Clinical annotations and
driver oncogenotypes for these cell lines are listed in Table S1.
H1299 and H1355 cells were treated long-term (>6 months) with
increasingdosesofpaclitaxel-carboplatindoublet, given incycles
of drug on (4 days) and drug off (1–2weeks). Cellswere character-
ized for their drug-response phenotypes after different treatment
cycles, with T[n] denoting cell line variant developed after ‘‘n’’ cy-
cles of doublet therapy. We thus developed H1299 variant series
consisting of T5, T10, T15, and T18 and H1355 isogenic cell line
series with T4, T8, T13, and T16 resistant variants. These variants
showed progressive increase in resistance to paclitaxel-carbo-
platinwith increasing treatmentcycles (Figures1Aand1C), reach-
ing >50-fold increases in IC50 in H1299 T18 and H1355 T16
(Figures 1B and 1D). Drug resistance persisted in limiting dilution
clonogenic assayswith continuous exposure to paclitaxel-carbo-
platin for 2–3 weeks (Figures 1E–1H).
Resistant Cell Line Variants Show Decreased Response
to Taxane-Platin Chemotherapy In Vivo and
Cross-Resistance to Multiple Drugs In Vitro
To validate the taxane-platin resistance phenotype in vivo, we
grew subcutaneous xenografts of H1299 parental and H1299
T18 cells and treated tumor-bearing mice with three cycles
of docetaxel-cisplatin doublet chemotherapy. While H1299
parental xenografts showed a dramatic reduction in tumor
burden compared to the vehicle-treated group (Figure 1I; **p =
0.002), H1299 T18 tumors showed a non-significant response,
confirming resistance (Figure 1J). This also confirmed cross-
resistance to docetaxel-cisplatin standard therapy.
Consistent with previously published reports that suggested
the involvement of MDR1 in taxane resistance (Lemontt et al.,
1988; Roninson et al., 1986), we detected increased mRNA
and protein expression of MDR1 in both H1299- and H1355-
resistant variants (Figures S1A–S1D), decreased drug accumu-
lation (Figure S1E), and partial re-sensitization to the doublet
upon genetic/pharmacological inhibition (Figures S1F–S1H). To
characterize the multi-drug-resistance phenotype, we tested
several standard and targeted agents (Figure S2A). Resistant
variants were found to be cross-resistant to docetaxel, doxoru-
bicin, vinorelbine, and depsipeptide, which are known MDR1
substrates (Figure S2B). Cells remained sensitive to carboplatin
as single agent, consistent with the low dose used and its estab-
lished mechanism of action (Busschots et al., 2015). ExtendedIncreasing Resistance to Paclitaxel-Carboplatin Chemotherapy
r long-term treatment with drug on/drug off cycles of paclitaxel-carboplatin. P,
otherapy. Values on the x axis indicate paclitaxel concentration (nM) in the drug
epresents mean ± SD of eight replicates.
lues represent paclitaxel concentration (in nM) in the 2:3 w/w drug combination.
m post-test for linear trend following one-way ANOVA.
tative plate images for H1299 (E) and H1355 (G) cells are shown. Drug values
ounting stained colonies from colony-formation assays. For parental cell lines,
e for two-fold serial dilutions. Error bars represent mean ± SEM.
ed (n = 8 per group) to receive vehicle or docetaxel + cisplatin once a week for
C3). Error bars represent mean ± SEM. Groups were compared using two-way
ts, two-way ANOVA: **p = 0.002, Sidak’s test at C3: ****p < 0.0001; H1299 T18
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drug-free culturing for >4 months resulted in partial reversal
of paclitaxel-carboplatin resistance (Figures S2C–S2F), suggest-
ing transient mechanisms in addition to stable changes. When
we expanded our panel of drug-resistant models to H1693
and HCC4017 cell lines, we found that both developed taxane-
platin resistance upon long-term exposure (Figures S3A–S3D),
but HCC4017 T5 did not show increased MDR1 (Figures S3E–
S3H). These findings led us to investigate other molecular
changes in taxane-platin resistance.
Gene Expression Profiles of Preclinical Models Yield a
Resistance-Associated Gene Signature
To investigate the molecular changes accompanying the devel-
opment of NSCLC resistance to chemotherapy, we performed
genome-wide mRNA expression profiling of the entire progres-
sively resistant, isogenic H1299 and H1355 cell line series. We
fitted a linear regression model on microarray data to systemat-
ically identify genes that showed a progressive increase or
decrease in expression consistent with increasing drug resis-
tance represented by the log-transformed IC50 values across
the entire series of progressed lines.We identified 3,752 differen-
tially expressed genes in the H1299-resistant series and 595
genes in the H1355-resistant series at a false discovery rate of
0.1 (Figure 2A). We then performed stringent filtering of expres-
sion data to only select for genes that exhibited overlap between
the two progressively resistant NSCLC cell line models. We
further required these changes to occur in vivo in H1299 xeno-
grafts. 51 upregulated and 59 downregulated genes overlapped
between the H1299- and H1355-resistant cell line series (Fig-
ure 2B), while intersection with xenograft tumor profiles (H1299
T18 versus H1299 parental xenografts; Figure 2C) identified 14
upregulated and 21 downregulated genes whose expression
differences were sustained in vivo (Figure 2D). These 35 genes
(Figure 2E) formed our preclinical resistance signature.
Evaluation of Preclinical Resistance Signature in
Neoadjuvant-Treated NSCLC Patient Tumors Identified
KDM3B as an Important Correlate of Poor Recurrence-
Free Outcome and a Druggable Resistance Target
To identify clinically relevant drug-resistance targets, we
tested our 35-gene resistance signature on a cohort of 65Figure 2. Gene Signature fromChemoresistantModels Clusters Neoad
Identifies KDM3B as a Significant Contributor to Poor Recurrence-free
(A) Linear regression model was fitted on microarray data to identify genes that w
cell lines (P) and four resistant variants per model were analyzed. Differentially ex
downregulated). FDR = 0.1.
(B) Common up- and downregulated genes across the two resistant cell line ser
(C) Differential gene expression analysis on xenograft microarray data (H1299 T1
(D) Gene lists obtained from cell line and xenograft microarray analyses were over
are from hypergeometric tests.
(E) Heatmap representation of the expression pattern of 35-gene resistance sign
(F) Using mRNA expression of 35 genes, unsupervised hierarchical clustering of n
found to separate the patients into two major groups.
(G) Kaplan-Meier survival analysis of the two groups of neoadjuvant-treated NSC
(p=0.001; hazard ratio =2.78; 95%confidence interval [CI], 1.46–5.29). Survival p v
(H) Cox multivariate regression identified individual contributions of the 35 gene
(i.e., exp [regression coefficient]), and the y axis represents log (p values) for
recurrence-free patient survival (hazard ratio = 10.28, p = 0.025).
See Tables S2–S4.NSCLC patients (annotated in Table S2) who had received
platin-based neoadjuvant chemotherapy, with taxane-platin
doublet administered prior to surgical resection. Resected
tumor samples were profiled by microarrays. Based on the
35-gene preclinical signature, unsupervised hierarchical clus-
tering separated the chemotherapy-treated patient tumors
into two major groups (Figure 2F). Kaplan-Meier survival
analysis revealed significant differences in recurrence-free
survival (Figure 2G). Group 2 exhibited significantly worse
cancer recurrence-free prognosis than Group 1 patients (haz-
ard ratio = 2.78, p = 0.001, adjusted for clinical covariates in
Table S3).
We further evaluated the individual contribution of the 35
genes in the signature using Cox multivariate regression (Table
S4) and focused on upregulated genes as potential therapeutic
targets. Among the 14 genes that were commonly upregulated
in preclinical resistance models, the gene that showed the
largest hazard risk for poor recurrence-free outcome in neoadju-
vant-treated NSCLC patients was the JmjC lysine demethylase
KDM3B (hazard ratio = 10.28, p = 0.025; Figure 2H), a druggable
enzyme. Notably, two of the downregulated genes in our 35-
gene signature, MAGEA1 and ANGPT1, are known to be sup-
pressed by KDM3B (GEO: GSE30294) (Kim et al., 2012). We
thus decided to explore KDM3B given that it represents an
actionable enzyme target.
Neoadjuvant-Treated NSCLC Tumors Show Increased
KDM Expression
KDM3B protein levels were evaluated in the same cohort of neo-
adjuvant-chemotherapy-treated NSCLC tumors by immunohis-
tochemistry (IHC) of specimens available in a tissue microarray.
Group 2 patients (who had poor recurrence-free survival)
showed higher overall KDM3B IHC scores than Group 1 patients
(Figure 3A). We then evaluated the mRNA expression of other
members of the KDM enzyme family in the NSCLC patients (66
neoadjuvant treated and 209 chemo-naive; annotated in Table
S2). NSCLC patient tumor cells surviving standard neoadjuvant
chemotherapy expressed higher overall KDM3A and KDM4A
mRNA levels than chemo-naive tumors (Figure 3B; p value
adjusted for clinical variables by multivariate analysis shown in
Table S5).juvant-TreatedNSCLCPatients Based onRelapse-free Outcome and
Survival
ere progressively up-/ downregulated with increasing drug resistance. Parental
pressed genes are represented in the volcano plots (red, upregulated; green,
ies are shown. p values are from hypergeometric tests.
8 resistant versus H1299 parental) using Student’s t test. FDR = 0.1.
lapped to identify common genes (14 upregulated, 21 downregulated). p values
ature in resistant cell lines and xenografts.
eoadjuvant-treated NSCLC patients (n = 65, mainly taxane-platin treated) was
LC patients revealed significant differences in cancer recurrence-free survival
aluewasadjusted for clinical covariates (Coxmultivariate regression; TableS3).
s to poor recurrence-free survival (Table S4). The x axis depicts hazard ratios
the 14 upregulated genes. KDM3B showed the largest hazard risk for poor
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Chemoresistant Cells Show Increased Expression of
JmjC Histone Lysine Demethylases and Altered Histone
Methylation Levels
Although KDM3B was the only histone demethylase that
made it into the 35-gene resistance signature because it was
progressively upregulated throughout the resistant series, was
common to both H1299 and H1355 cell line models, and
showed increased expression in vivo, several other JmjC
family members were also overexpressed in resistant models.
For example, KDM5A, JMJD4, and JMJD8 were among the
other upregulated genes in the H1299-resistant cell line series
(false discovery rate [FDR] = 0.1, p < 0.05). In-vivo-grown
H1299 T18 tumors exhibited increased expression of KDM3A,
KDM4B, KDM5A, KDM5B, KDM6B, KDM7A, JARID2, JMJD4,
and JMJD6 (Figure S4A).
We therefore profiled the JmjC KDM gene family in chemore-
sistant versus parental cells by qRT-PCR and found general up-
regulation of JmjC KDMs, including KDM3B (Figures 3C and
S4B). We also noted strong upregulation of the H3K27 demethy-
lasesKDM6A,KDM6B, andKDM7A, andmodest upregulation of
the H3K4 demethylases KDM5A and KDM5B in H1299 T18 cells
(Figure 3C). We then queried the entire progressively resistant
H1299 series and found a consistent increase in KDM mRNA
expression with increasing resistance to paclitaxel-carboplatin
chemotherapy (Figure 3D).
To investigate the functional effects of JmjC KDM upregula-
tion in resistant cells, we performed mass spectrometry for
global histone post-translational modifications in histone ex-
tracts from H1299 T18 and H1299 parental cells. Consistent
with the upregulation of the H3K9me1 demethylase KDM3B,
we detected a global decrease in H3K9me1 and a subsequent
increase in H3K9me0 in H1299 T18 versus parental cells
(Figure 3E, left). We also found decreased K9me1 in K14
acetylated H3 and a corresponding increase in K9/K14 un-
modified (me0, ac0) levels in both H1299 T18 and H1355
T16 cell lines (Figure S4C). In agreement with strong upre-
gulation of the histone3 K27me3/me2 demethylase KDM6B
in H1299 T18 cells, we observed decreased K27me3 and
K27me2 global levels and a corresponding increase
in K27me0 (Figure 3E, right) on H3.3, a histone3 variantFigure 3. Neoadjuvant-Treated NSCLC Patient Tumors and Chemo
Demethylases and Altered Histone Methylation
(A) Group 2 of neoadjuvant-treated patients (poor recurrence-free survival) showe
KDM3B IHC and corresponding tumor H&E staining are shown. Scale bar, 200 m
(B) Chemotherapy-treated patient tumors showed higher mRNA expression sco
normalized expression scores. The line indicates median value and whiskers the
clinical variables (*p < 0.05, ****p < 0.0001).
(C) Paclitaxel-carboplatin-resistant H1299 T18 cell line showed increased mRNA
Error bars represent mean ± SEM. p values are from two-way ANOVA (***p < 0.0
(D) Isogenic H1299 resistant cells showed progressive increases in JmjC KDM exp
post-test for linear trend (*p < 0.05, **p < 0.01, ****p < 0.0001).
(E) Global changes in histone lysinemethylationweremeasured bymass spectrom
9–17; right, H3.3: 27–40) that showed K9 or K27 methylation, respectively. Left p
mean ± SEM (n = 2). p values are from Fisher’s LSD test post two-way ANOVA,
(F) H3K27me3 ChIP-seq enrichment plots for up- and downregulated genes iden
represents the genomic regions from 50 to 30 and the y axis represents read dep
(G) H3K4me3 average distribution plots for differentially expressed genes in
downregulated genes). TSS, transcription start site; TES, transcription end site.
See also Table S5 and Figure S4.deposited specifically in actively transcribed regions (Szenker
et al., 2011).
To gain insights into the effect of increased H3K27 and H3K4
demethylases on the transcriptional output of chemoresistant
cells, we performed chromatin immunoprecipitation sequencing
(ChIP-seq) for H3K27me3 and H3K4me3 marks in H1299
parental and H1299 T18 cells. First, correlating with increased
expression of H3K27me3 demethylases, we observed that
H1299-T18-resistant cells showed marked decrease in the
‘‘average’’ distribution of H3K27me3 across all transcribed re-
gions of the genome (Figure S4D). There was however no
decrease in average H3K4me3 distribution across all genes (Fig-
ure S4E). To specify the transcribed regions that exhibited
changes in H3K27me3 and identify altered H3K4me3 enrich-
ment, we used RNA sequencing (RNA-seq) to classify differen-
tially upregulated and downregulated genes in H1299 T18 versus
H1299 parental cells (fragments per kilobase of transcript per
million mapped reads [FPKM]R 1; FDR q = 0.05) and then eval-
uated their histone marks. We found that the upregulated genes
in H1299 T18 showed an overall decrease in the repressive
H3K27me3 signal throughout transcription start sites (TSSs)
and gene bodies (Figure 3F, left), whereas downregulated genes
selectively showed increased H3K27me3 at the TSS (Figure 3F,
right). Likewise, ChIP-seq for H3K4me3 revealed an increase in
H3K4me3 at the TSS of upregulated genes (Figure 3G, left), while
downregulated genes exhibited reduced H3K4me3 at the TSS
(Figure 3G, right). We thus detected functional changes in the
H3K4/H3K27 methylation landscape of resistant versus parental
cells that corresponded with transcriptional activation or repres-
sion of differentially expressed genes.
Chemoresistant Cells Are Hypersensitized to JmjC
Demethylase Inhibitors
To test the survival dependency of chemoresistant cells on JmjC
KDMs, we first employed a pan-selective JmjC demethylase in-
hibitor, JIB-04 (Wang et al., 2013). H1299 T18 cells were several-
fold hypersensitized to JIB-04 E isomer compared to parental
cells (Figure 4A), while the inactive Z isomer had no effect. We
then tested the KDM5/KDM6 subfamily inhibitor GSK-J4 (Krui-
denier et al., 2012). Again, H1299 T18 showed higher sensitivityresistant Cell Lines Exhibit Elevated Expression of JmjC Histone
d higher KDM3B IHC scores than Group 1 patients. Representative images of
m.
res of KDM3A and KDM4A than chemo-naive tumors. The y axis depicts log2
10th and 90th percentiles. p values are adjusted after multivariate analysis of
expression of several JmjC KDMs compared to H1299 parental, by qRT-PCR.
01).
ression. Error bars represent mean ± SEM. p values are from one-way ANOVA
etry. The y axis denotes the percentage of the stated histone peptides (left, H3:
anel error bars represent mean ± SEM (n = 3). Right panel error bars represent
*p < 0.1, ***p < 0.001.
tified by RNA-Seq (FDR 0.05) in H1299 T18 versus H1299 parental cells. x axis
th.
H1299 T18 versus H1299 Parental cells (left panel upregulated, right panel
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to GSK-J4 than parental cells, and there was no effect on cell
viability with the inactive GSK-J5 (Figure 4B).
To investigate whether increased KDM expression and phar-
macological sensitivity to JmjC inhibitors accompanied the pro-
gressive increase in chemoresistance, we queried the entire
H1299 resistant series. In agreement with increased KDM upre-
gulation (Figure 3D), we saw a consistent decrease in IC50 values
to JIB-04 and GSK-J4 as cells progressed from H1299 parental
to the H1299 T18 variant (Figures 4C and 4D).
To explore the generality of increased sensitivity of taxane-
platin-resistant NSCLC cells to JmjC inhibitors, we tested other
resistant cell line variants. H1355 T16, which had upregulation
of KDM3B and KDM6A (Figure S4B), showed higher sensitivity
to JIB-04 (Figure 4E) and GSK-J4 (Figure 4F) than H1355
parental. Other taxane-platin-resistant cell lines, including
HCC4017 T5 and H1693 T8, were also more sensitive to JIB-
04 than their corresponding parental cells (Figures 4G, S5A,
and S5B), with a fold-sensitivity proportional to their level of
taxane-platin resistance. Of note, HCC4017 and H1693 parental
cell lines were already highly sensitive to the KDM5/KDM6-spe-
cific inhibitor GSK-J4 (Figure S5C). Their HCC4017-T5- and
H1693-T8-resistant variants, although hypersensitized to JIB-
04, did not show any further reduction in GSK-J4 IC50 values
(Figure S5C), suggesting that these cells may have acquired
resistance independently of H3K4 or H3K27me3 demethylases.
Indeed, qRT-PCR analysis revealed modest upregulation of
other KDMs in HCC4017 T5 and H1693 T8 (Figures S5D and
S5E), including known JIB-04 targets (Wang et al., 2013).
To evaluate if the hypersensitivity of taxane-platin-resistant
cells was specific to JmjC KDM inhibitors or represented a gen-
eral epigenetic susceptibility, we tested other compounds inhib-
iting 2-OG oxygenases, histone methyltransferases (HMTs),
LSD1 demethylase, histone acetyltransferases (HATs), histone
deacetylases (HDACs), DNA methyltransferases (DNMTs), or
bromodomains (BRDs). We did not see significant differences
in IC50 values of any of these drugs between parental cells and
taxane-platin-resistant variants (Figures 4H and S6; Table S6).
Of particular note was the lack of hypersensitivity to HMT inhib-
itors and 2-OG oxygenase inhibitors (Table S6), consistent with
no general expression changes in these enzyme families (GEO:
GSE77209). Our studies have thus uncovered a specific, target-
able epigenetic vulnerability to Jumonji inhibition that can be ex-
ploited to treat NSCLCs that develop resistance to taxane-platin
chemotherapy.Figure 4. Chemoresistant Cell Lines Show Increased Sensitivity to Jm
(A and B) H1299 T18 cells showed hypersensitivity to JIB-04 active ‘‘E’’ isomer (
(JIB-04 ‘‘Z’’ isomer and GSK-J5) had no effect. Each data point represents mean
(C and D) IC50 plots for H1299-resistant series for response to JIB-04 (C) and G
one-way ANOVA, followed by Dunnett’s multiple comparisons with H1299 parenta
trend.
(E and F) H1355-T16-resistant variant was hypersensitized to JIB-04 active E isom
Each data point represents mean ± SD from eight replicates per drug dose.
(G) IC50 values show general hypersensitivity of H1299 T18, H1355 T16, HCC401
two-way ANOVA (p < 0.01).
(H) Log10 IC50 values for standard, targeted and epigenetic drugs for H1299 T18 ch
inhibitors of KDM, LSD1, HMT, HDAC, HAT, DNMT, and BRD. The red dotted line
10-fold cut-off for sensitization.
See also Figures S5 and S6 and Table S6.JIB-04 or GSK-J4 Treatment Results in Reversal of a
Subset of Transcriptional Programs Deregulated in
Taxane-Platin-Resistant Cells
In agreement with the hypersensitivity of chemoresistant cells to
JmjC inhibitors, we observed that short-term (24-hr) treatment
with 0.2 mM JIB-04 (Figures S7A and S7B) or 1 mMGSK-J4 (Fig-
ures S7C and S7D) led to gene expression changes selectively in
H1299-T18-resistant cells with minimal transcriptional changes
in H1299 parental cells (p % 0.05). Importantly, JmjC inhibitor
treatment of H1299 T18 partially reversed expression changes
acquired during the development of taxane-platin resistance
(Figures S7E and S3F; Table S7). Furthermore, gene set enrich-
ment analysis (GSEA) using curated gene sets from molecular
signatures database (MSigDB) (Subramanian et al., 2005) re-
vealed reversal of a subset of transcriptional programs in
H1299 T18 cells upon JmjC inhibitor treatment, with a significant
overlap between JIB-04 and GSK-J4 (Figure 5A). Out of the 214
gene sets that were depleted after resistance development in
H1299 T18 cells, 38 gene sets (20%) were enriched (reversed)
by both JIB-04 and GSK-J4. These 38 overlapping gene sets
(Table S8) included functionally relevant categories such as
genes with H3K4me3 and H3K27me3 marks (MSigDB, M1941;
Meissner et al., 2008; shown in Figure 5A, left), as well as
SUZ12 ChIP-on-chip targets, indicative of genes regulated by
H3K27me3 (MSigDB, M9898; Table S8; Ben-Porath et al.,
2008). Also included in the overlap were apoptotic gene sets
such asMDM4 target genes, TP63 target genes, and TP53 target
genes (Table S8). A gene set representing genes upregulated in
apoptotic tissues (MSigDB, M5681; Martoriati et al., 2005) en-
riched by both JmjC inhibitors is shown in Figure 5A (right).
To gain insights into the H3K4me3 and H3K27me3 dynamics
revealed by GSEA (Figure 5A, left), we performed detailed pro-
moter bivalency analyses of our ChIP-seq data. We first identi-
fied H3K4me3 and H3K27me3 bivalent gene promoters in
H1299 parental and H1299 T18 cells. Genes were classified as
bivalent if both H3K4me3 and H3K27me3 were R4-fold over
input in the TSS ±500 bp region. We found that there was an
overall decrease in the total number of bivalent genes in H1299
T18 compared to parental cells (Figure 5B, bar graph). A great
majority of these genes (80%) showed at least a 2-fold signal
loss. We next classified the ‘‘bivalency lost’’ genes by loss of
H3K4me3, loss of H3K27me3, or loss of both marks (Figure 5B,
pie chart). Many of the genes that had lost their bivalency in
H1299 T18, compared to H1299 parental, re-gained thesemarksjC KDM Inhibitors
A) as well as GSK-J4 (B), compared to H1299 parental. Inactive drug isomers
± SD from eight replicates per drug dose.
SK-J4 (D). Data represent mean ± SD. Statistical significance was tested by
l (**p < 0.01, ***p < 0.001). p values listed on graphs are from post-test for linear
er (E) and GSK-J4 (F), but not to inactive isomers, compared to H1355 parental.
7 T5, and H1693 T8 to JIB-04. Data represent mean ± SEM. p values are from
emoresistant versus H1299 Parental cells. Epigenetic drugs (blue dots) include
denotes the 10-fold cut-off for cross-resistance, and the green dotted line is the
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(at least a 1.5-fold increase) after short-term GSK-J4 or JIB-04
treatment of T18 cells (shown by category in Figure 5C).
To validate the apoptotic gene set enrichment uncovered by
GSEA on our microarray data, we queried known apoptotic
genes from the Martoriati gene set (Figure 5A, right) in our
RNA-seq dataset. As shown in Figure 5D, pro-apoptotic genes
were significantly upregulated by short-term JmjC inhibitor
treatment of T18 cells. Additionally, these and some other pro-
apoptotic/anti-proliferative genes were confirmed by qRT-PCR
to be upregulated by both JIB-04 and GSK-J4, whereas prolifer-
ative/oncogenic genes were significantly downregulated in
JmjC-inhibitor-treated T18 cells (Figure S8A). ChIP-seq traces
of sample pro-apoptotic genes upregulated by JmjC inhibitors,
DDIT4 and BNIP3 are shown in Figures 5E and 5F, respectively,
exhibiting greater enrichment of the H3K4me3 activating mark.
In contrast, histone marks at the MDR1 locus were not altered
by JmjC inhibitor treatment, nor was MDR1 expression, as ex-
pected from its genetic amplification (Figures S8B–S8F).
These analyses confirmed that major changes in the
H3K4me3/H3K27me3 dynamics accompany the development
of chemoresistance and that short-term JmjC inhibitor treatment
can partly reverse these changes, killing drug-resistant cells with
high potency.
Chemoresistant Tumors Show Increased Response to
GSK-J4 and JIB-04 In Vivo
To evaluate the response of taxane-platin-chemoresistant
NSCLC cells to JmjC inhibitors in vivo, we established subcu-
taneous xenografts of H1299 parental and H1299 T18 cells
and compared their response to GSK-J4 or JIB-04. GSK-J4
caused a significant reduction in tumor volumes selectively in
H1299 T18 xenografts (p < 0.0001) (Figure 6A and 6B). Treated
T18 tumors also showed a significant decrease in final tumor
weights (p < 0.01) (Figure 6B, right), without mice body weight
loss (Figure S9A). For the JIB-04 study, tumor-bearing mice
were randomized to receive 5 mg/kg, 20 mg/kg, or 50 mg/kg
treatment or vehicle. At all doses, JIB-04 resulted in greater
percent reduction in final tumor volumes of H1299 T18
compared to H1299 parental (Figures 6C and 6D). JIB-04 treat-
ment preferentially slowed T18 tumor growth and decreased tu-Figure 5. JIB-04 and GSK-J4 Cause Reversal of Deregulated Transcript
and Induction of Pro-apoptotic Genes in Chemoresistant Cells
(A) GSEA of differentially expressed gene lists frommicroarray against MSigDB cu
T18-resistant versus H1299 parental cells are enriched by 24-hr treatment with J
tests. Two of the 38 overlapping gene sets are shown. Left: genes with H3K4me
apoptotic tissues (Martoriati et al., 2005; M5681). NES, normalized enrichment s
(B) ChIP-seq analysis confirmed loss of bivalent genes in H1299 T18 versus paren
marks (pie) are shown.
(C) Genes in each of the bivalency lost categories depicted in the pie chart in (B) w
JIB-04-treated H1299 T18 cells.
(D) Genes from theMartoriati et al. apoptotic gene set identified in (A) were confirm
from biological duplicates. Significance was tested using the powerful FDR (q)
Yekutieli; *q < 0.05, **q < 0.01, ***q < 0.001, ****q < 0.0001.
(E) ChIP-seq traces for the pro-apoptotic, upregulated gene DDIT4, showing incr
cells.
(F) ChIP-seq traces for BNIP3 upregulated gene, showing broader H3K4me3 en
1 mM, 24 hr (for both E and F).
See also Figures S7 and S8 and Tables S7 and S8.mor growth rate, as seen by increased tumor doubling times
(Figure 6E), without any toxicity on treated mice (Figure S9A).
To evaluate whether the targeted KDM enzymatic activity
was reduced in the JmjC-inhibitor-treated tumors in vivo, we
measured histone demethylase activity in drug versus vehicle
treated tumor lysates by ELISA. Chemoresistant H1299 T18
xenografts had higher H3K4me3, H3K9me3, and H3K27me3
demethylase activity than H1299 parental tumors (Figure 6F),
in agreement with increased KDM expression. KDM6 inhibitor
GSK-J4 significantly inhibited H3K27me3 demethylase activity
in H1299 T18 xenografts (Figure 6F, right), without reducing
H3K4me3 or H3K9me3 demethylase activity (Figure 6F, left
andmiddle). The pan-JmjC inhibitor JIB-04 significantly inhibited
H3K4me3, H3K9me3, and H3K27me3 demethylase activity in
H1299 T18 xenografts (Figure 6G). In addition, we saw evidence
of cytostatic/cytotoxic effects in JmjC-inhibitor-treated chemo-
resistant xenografts (Figures S9C–S9E).
We then validated the hypersensitivity of chemoresistant
tumors to JIB-04 and GSK-J4 in an additional in vivo
model, comparing treatment response in H1355 parental versus
H1355 T16. JmjC-inhibitor-treated H1355 parental xenografts
continued to grow in volume throughout the 28 days of treatment
(Figure 6H, left), whereas treated H1355 T16 tumors exhibited
significant tumor shrinkage (Figure 6H, right). No appreciable
toxicity was seen in JIB-04- or GSK-J4-treated mice (Fig-
ure S9B). Both in vivomodels confirmed the increased sensitivity
of taxane-platin-chemoresistant tumors to JIB-04 and GSK-J4.
Taken together, these data provide proof of principle for the
use of JmjC inhibitors to target drug-resistant NSCLCs.
JmjC KDM Inhibitors Synergize with Taxane-Platin
Standard Chemotherapy and Prevent Emergence of
Drug Tolerance
Given the hypersensitivity of chemoresistant cells to JmjC
inhibitors and the transcriptional reprogramming seen in resis-
tant cells, we asked whether JIB-04 or GSK-J4 would synergize
with taxane-platin chemotherapy in killing chemoresistant
clones. Using JIB-04 or GSK-J4 doses that were predetermined
to not cause complete growth inhibition as single agents, both
of these drugs were effective in synergistically inhibitingional Programs, Regain of H3K4me3-H3K27me3 Promoter Bivalency,
rated gene sets revealed transcriptional programs that were depleted in H1299-
IB-04 (0.2 mM) or GSK-J4 (1 mM). p values signify overlap by hypergeometric
3 and H3K27me3 (Meissner et al., 2008; M1941), Right: genes upregulated in
core. p values under GSEA plots are nominal p values.
tal cells. Number of bivalent genes (bar graph) and breakdown by lost or gain of
ere probed for their regain status (at least a 1.5-fold increase) in GSK-J4- and
ed to be upregulated by GSK-J4 by RNA-seq. Error bars indicate mean ± SEM
approach of two-stage linear step-up procedure of Benjamini, Krieger, and
eased H3K4me3 (blue highlight) in GSK-J4- versus DMSO-treated H1299 T18
richment in GSK-J4-treated versus DMSO-treated H1299 T18 cells. GSK-J4:
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H1299-T18-chemoresistant colonies surviving taxane-platin
treatment (indicated by positive delta Bliss in Figures 7A and 7B).
We also investigated blocking the emergence of drug-tolerant
colonies from taxane-platin-sensitive, chemo-naive cell lines.
H1299 parental cells were exposed to paclitaxel-carboplatin un-
der conditions that allowed for a surviving subpopulation. We
then evaluated the impact of sublethal doses of various epige-
netic compounds in inhibiting colony forming ability of these tax-
ane-platin ‘‘persister’’ cells (Figure 7C). Only the JmjC inhibitor
prevented the emergence of drug-tolerant colonies from
H1299 parental cells, whereas inhibitors of other epigenetic en-
zymes did not (Figure 7C). Next, we assessed if JmjC inhibition
could block the outgrowth of persister colonies from other che-
mosensitive NSCLC cell lines. H1355, HCC4017, and H1693
parental cells were exposed to their respective predetermined
paclitaxel-carboplatin doublet concentrations that allowed for
a surviving subpopulation. Sublethal doses of GSK-J4 inhibited
the outgrowth of these taxane-platin drug-tolerant colonies
(Figure 7D).
We therefore evaluated the impact of JmjC inhibitors in
combination with standard taxane-platin chemotherapy in vivo.
Combination of JIB-04 or GSK-J4 with paclitaxel-carboplatin
chemotherapy resulted in significantly greater tumor growth inhi-
bition of H1299 parental xenografts than single agents and gave
a synergistic response (Figure 7E, top, positive delta Bliss). There
was a significant reduction in tumor burden compared to either
therapy alone (Figure 7E bottom, tumor weights), without general
toxicity.
Our results thus present a new therapeutic opportunity for
not only targeting of NSCLCs after development of drug resis-
tance but also possibly preventing the emergence of chemore-
sistant subpopulations and achieving greater response in che-
mosensitive lung cancers treated with standard taxane-platin
chemotherapy.
DISCUSSION
We have established preclinical models of NSCLC resistance to
taxane-platin doublet chemotherapy and identified upregulationFigure 6. JmjC-Inhibitor-Treated Chemoresistant Tumors Have Lowe
and JIB-04 In Vivo
(A and B) GSK-J4 treatment significantly reduced final tumor burden of H1299 T1
The y axis depicts percent tumor volumes normalized to average vehicle tumor vol
p values for tumor volume growth are from two-way ANOVA (ns, not significant
unpaired t test (**p = 0.007).
(C and D) At all doses, JIB-04 caused a greater percent reduction in H1299 T18 tum
n = 6–8 mice per group. The y axis depicts percent tumor volumes normalized to a
using non-linear regression. Drug response was compared using a two-way ANOV
H1299 T18, ****p < 0.0001.
(E) JIB-04 treatment slowed tumor growth and increased doubling time of treate
(<25% change). Doubling times were derived from exponential growth curves in
(F) H3K4me3/H3K9me3/K27me3 demethylase activity in tumor lysates from GS
(*p < 0.1, **p < 0.01, ***p < 0.001).
(G) JIB-04 treatedH1299 T18 xenografts showed significant reduction in H3K4me
unpaired t tests (*p % 0.05).
(H) Percent change in tumor volumes relative to the treatment start volume (1
p values are from two-way ANOVA (*p < 0.05, **p < 0.01, ****p < 0.0001).
See also Figure S9.of JmjC histone lysine demethylases as an underlying epigenetic
change co-developing with increasing chemoresistance and
leading to progressive sensitization to JmjC KDM inhibitors.
These findings define JmjC demethylases as promising thera-
peutic targets in drug-resistant NSCLCs and for potentially pre-
venting the emergence of taxane-platin drug tolerance.
Our work suggests that NSCLC cells may dynamically express
multiple JmjC KDMs, in line with recent similar observations in
glioblastoma (Liau et al., 2017). Further, KDMs may have a role
not only in survival from the first drug contact but also in main-
taining transcriptional plasticity and increasing epigenetic alter-
ations during the progression toward robust drug resistance.
Chemoresistant cells appear to be epigenetically addicted,
becoming specifically hypersensitized to JmjC KDM inhibitors.
Future genetic studies will need to determine which JmjC deme-
thylases are the key mediators of this phenotype.
Due to their ability to regulate multiple transcriptional pro-
grams at once, epigenetic mechanisms might serve to restore
the cellular signaling balance (Mair et al., 2014) that is perturbed
by chemotherapy stress, acting as a defense mechanism to pro-
tect cells from further insults. It is unclear if JmjC-enzyme-over-
expressing subpopulations exist in the original population or are
acquired de novo, upon selective pressure. Our studies suggest
that the resistance is likely manifested as a combination of both
intrinsic and acquired changes. While GSK-J4 eliminated the
emergence of drug-resistant colonies in a short-term colony
formation assays, our long-term drug treatment studies revealed
that resistant cells were also acquiring permanent/genetic
changes over time, nevertheless maintaining their hypersensitiv-
ity to JmjC inhibitors.
Since our previous studies have shown that normal human
bronchial epithelial cells are not sensitive to JmjC inhibition
(Wang et al., 2013), our findings suggest that there is a therapeu-
tic window for lung cancer therapy, while also raising the possi-
bility of extending the utility of JmjC inhibitors to other drug-
resistant solid tumors. Pharmacological targeting of JmjC
KDMs could help prevent the development of drug resistance
while also providing a therapeutic option to treat chemoresistant
tumors.r Histone Demethylase Activity and Increased Response to GSK-J4
8 xenografts (B); response in H1299 parental xenografts was not significant (A).
ume at the end of treatment. Data represent mean ±SEM; n = 5mice per group.
, ****p < 0.0001). Tumor weights (B, right) were compared using an two-tailed
or volumes (D) than in H1299 parental tumors (C). Data represent mean ±SEM;
verage vehicle tumor volume on day 14. Exponential growth curves were fitted
A. For the 5mg/kg versus vehicle group in H1299 parental, **p = 0.001, and for
d H1299 T18 tumors by 69%, with minimal effect on H1299 parental tumors
(C) and (D).
K-J4-treated mice. p values are from Fisher’s LSD test post one-way ANOVA
3, H3K9me3, and H3K27me3 demethylase activity. p values are from two-tailed
20 mm3) is shown for H1355 parental (left) and H1355 T16 (right) xenografts.
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EXPERIMENTAL PROCEDURES
Cell Lines
NSCLC lineswere obtained from the HamonCancer Center Collection (Univer-
sity of Texas Southwestern Medical Center). Cell lines were DNA fingerprinted
using PowerPlex 1.2 kit (Promega) and confirmed to be mycoplasma-free
using e-Myco kit (Boca Scientific). Cells were maintained in RPMI-1640 (Life
Technologies) with 5% FBS at 37C in a humidified atmosphere containing
5% CO2.
In Vitro Drug Assays
NSCLC lines were treated with paclitaxel-carboplatin combination, given in a
2:3 w/w ratio, to mirror the clinical dosage values of 225 mg/m2 paclitaxel
and 330 mg/m2 carboplatin. Considering the molecular weights of the two
drugs, this translates to an1:3.4 molar ratio. Drugs were given in cycles, con-
sisting of 4–5 days of drug treatment and 1–2 weeks of drug-free culturing to
allow the surviving cells to repopulate. Treatment was started with 23–33 IC50
doses, and doses were increased with increasing treatment cycles, ultimately
reaching 303–503 IC50, depending on the cell line. Untreated parental
cells were maintained at all times for comparison. Cell viability after 4-day
treatments was assessed in 96-well plates using standard 3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt (MTS) assays (Promega). Drugs were tested in serial dilutions, totaling
eight different drug concentrations, with eight replicates per concentration.
Response was validated in replicate plates (n R 3).
In Vivo Studies
Animals were housed under standard, sterile conditions at The University of
Texas Southwestern (UTSW) animal facility. All experiments were carried out
under approved Institutional Animal Care and Use Committee (IACUC) proto-
cols and followed UTSW animal care procedures. Experimental details are
provided in Supplemental Experimental Procedures.
Patient Tumors
Human specimens and clinical data were used after full de-identification under
MD Anderson institutional review board (IRB)-approved/exempted protocols.
This included both chemo-naive and neoadjuvant-treated tumors and com-
plete histopathological and clinical annotation. Fresh frozen tumor samples
from the time of resection were used for Illumina gene expression profiling,
and some were formalin-fixed, paraffin-embedded (FFPE) tumors for tissue
microarrays.
Microarrays
Gene expression profiling was performed using Illumina HumanWG-6 V3
BeadArrays (forNSCLCpatient tumors)or IlluminaHumanHT-12V4BeadArrays
(for cell lines, xenografts). Cell lineandxenograftmicroarrays includedbiological
replicates (cell lines: five for parental, three formost resistant variant, and two for
each intermediate time point; xenografts: three tumors each for parental and
resistant group). Data were pre-processed using the R package mbcb for
background correction (Ding et al., 2008) and then log-transformed and quan-
tile-normalized with the R package preprocessCore or using in-house MATRIXFigure 7. JmjC KDM Inhibitors Synergize with Paclitaxel-Carboplatin
from Chemosensitive NSCLCs In Vitro and In Vivo
(A and B) Combination of JIB-04 (A) or GSK-J4 (B) with standard paclitaxel-carbop
Error bars represent mean ± SD from duplicate assays. p values are from two-ta
indicated by positive DBliss.
(C) Sublethal doses of the JmjC KDM inhibitor GSK-J4 (but not other epigeneti
colonies from chemosensitive H1299 parental. Representative images from repli
(D) GSK-J4 also blocked the emergence of paclitaxel-carboplatin drug-tolerant
H1693.
(E) H1299 Parental tumor volumes during in vivo combination treatment are shown
tests on tumor volumes represent comparison of each treatment group with the
****p < 0.0001). DBliss for (Pac + Carb + JIB-04) combination = +13.8%; DBliss fo
tumor weight comparisons are from two-tailed unpaired t tests (*p < 0.1, **p < 0software (microarray transformation in Excel). See Supplemental Experimental
Procedures for microarray analysis details.
Statistical Methods
All statistical tests were performed using GraphPad Prism 6/7. Dose-response
curves and IC50 values were also calculated using in-house DIVISA (database
of in vitro sensitivity assays; L.G., unpublished data). For synergy estimation,
DBliss excess was calculated as shown previously (Wilson et al., 2014). Bliss
expectation was calculated as A + B (A3 B), where A and B denote the frac-
tional responses fromdrugs A andB given individually. The difference between
Bliss expectation and observed response from combination of drugs A and B
at the same doses is the DBliss excess.
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